President Trump’s Historic Move to Reschedule Cannabis and Boost Research

The landscape of cannabis in America just experienced a seismic shift. On December 18, 2025, President Donald J. Trump signed a landmark executive order that does more than just make headlines—it fundamentally changes how the federal government views the plant we know and love.

For years, the cannabis and hemp industries have operated in a gray area, balancing state legalization with federal prohibition. But with this new directive, the White House is acknowledging what millions of Americans already know: cannabis has legitimate medical value.

At Modifi Brands, we have always believed in the power of cannabinoids to improve lives. Whether you use our CBD for balance or our VĪBZ THC products for a deeper experience, this news validates your choices. Let’s break down exactly what happened, what "Schedule III" really means, and how this impacts you as a consumer.

The Executive Order: A New Era for Cannabis

President Trump’s order directs the Attorney General to expedite the process of moving marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This is a massive departure from decades of policy.

Since 1970, cannabis has been stuck in Schedule I, sitting alongside substances like heroin and LSD. The government’s official stance was that it had "no currently accepted medical use" and a "high potential for abuse." Anyone who has used our VĪBZ gummies to unwind or our CBD tinctures to manage stress knows how outdated that classification was.

By moving it to Schedule III, the federal government is finally admitting that cannabis is less dangerous than previously claimed and has recognized medical benefits. This puts it in the same category as Tylenol with codeine or testosterone—controlled, yes, but acknowledged as medicine.

Why This Matters for Research

One of the biggest hurdles for the cannabis industry has been a lack of high-quality, federal research. Because cannabis was a Schedule I drug, scientists had to jump through impossible hoops to study it. This left doctors and patients guessing about dosages, interactions, and long-term effects.

The President’s fact sheet explicitly states that this order is designed to "improve medical marijuana and cannabidiol (CBD) research." The administration wants to use "real-world evidence" to inform standards of care.

This is huge for transparency. It means we will start seeing more clinical trials and data-backed studies that confirm the safety and efficacy of cannabinoids. For a company like Modifi Brands, which prides itself on quality and transparency, this is a welcome change. It allows the science to finally catch up with the consumer experience.

Spotlight on CBD and Hemp Access

While the headlines are focused on "marijuana," there is a critical component of this order that directly affects hemp and CBD consumers.

The executive order directs the White House to work with Congress to ensure Americans have access to "appropriate full-spectrum CBD products." This is a direct nod to the health benefits of the entourage effect—where cannabinoids like CBD, THC, and minor compounds work better together than they do alone.

For years, the FDA has dragged its feet on regulating CBD, leaving the market in a state of confusion. This directive signals a push to clear up that confusion. It aims to protect access to safe, tested products while cracking down on bad actors selling dangerous, unregulated synthetics.

If you are a fan of our full-spectrum CBD oils, this is great news. It suggests a future where these products are not just tolerated, but regulated and standardized, ensuring you always get exactly what is on the label.

What is Schedule III?

You might be wondering, "Does this mean weed is legal now?"

Not exactly. Schedule III does not mean full recreational legalization at the federal level. Here is the breakdown of what Schedule III actually changes:

• Medical Recognition: It formally recognizes the medical utility of cannabis.

• Tax Relief for Businesses: It likely eliminates the crushing 280E tax code, which prevented cannabis businesses from deducting standard business expenses. This helps companies survive and invest more in product development.

• Research Freedom: It removes the strictest barriers to scientific study.

• Pharma Potential: It opens the door for pharmaceutical companies to develop cannabis-derived drugs more easily.

It does not automatically legalize recreational sales nationwide. States will still have their own laws, and you still cannot buy "weed" at a gas station federally. However, it significantly lowers the temperature of the drug war and signals that the federal government is stepping out of the way of progress.

The Impact on VĪBZ and THC Products

Modifi Brands offers VĪBZ, a line that includes THC. You might be asking how this affects those products.

Currently, many THC products sold online operate under the 2018 Farm Bill, which legalized hemp-derived cannabinoids containing less than 0.3% Delta-9 THC on a dry weight basis. This legal loophole allowed for the explosion of the hemp-derived THC market.

President Trump’s order mentions working to "restrict the sale of products that pose serious health risks" while protecting access to "appropriate" products. This likely targets synthetic cannabinoids or untested "gas station weed" that gives the industry a bad name.

For reputable brands like Modifi, this push for regulation, by President Trump, is positive. We already prioritize testing and safety. A regulated market pushes out the sketchy competitors and highlights companies that are doing it right. It validates the space where VĪBZ operates—providing safe, enjoyable THC experiences to adults who want them.

Medical Marijuana for Seniors and Veterans

A touching part of the announcement was the focus on vulnerable populations. President Trump noted that one in ten seniors used cannabis in the last year, often to manage pain and improve quality of life.

The order proposes a pilot program that could allow Medicare beneficiaries to access CBD products. This is revolutionary. For the first time, we are talking about federal healthcare systems potentially covering or facilitating access to cannabinoids.

This aligns perfectly with our mission. We see customers of all ages turning to Modifi Brands for relief. Seeing the highest levels of government recognize that seniors and veterans deserve access to these natural alternatives is a massive validation of our industry’s purpose.

Economic Implications: The End of 280E?

For the business side of things, the move to Schedule III is a financial game-changer. Section 280E of the tax code has been a nightmare for cannabis companies. It essentially treats them as drug traffickers, taxing them on gross income without allowing for standard deductions like rent, payroll, or marketing.

Moving to Schedule III should kill 280E. This means cannabis companies will finally be taxed like normal businesses.

Why should you care? Because healthier businesses can innovate. They can lower prices. They can invest in better customer service and faster shipping. When the companies you buy from are not being strangled by the IRS, the consumer wins.

The Road Ahead: What to Watch

This executive order is a "directive." That means the President has told the agencies (like the DEA and HHS) what to do, but the paperwork still needs to be finished. The rulemaking process will be expedited, but it won’t happen overnight.

We will be watching closely to see how the "rulemaking process" unfolds. There will be public comment periods and likely some legal challenges from prohibitionist groups. However, the momentum is undeniable. The President of the United States has put his signature on a document that says cannabis is medicine. There is no putting the genie back in the bottle.

Modifi Brands: Ahead of the Curve

At Modifi Brands, we have always operated with the future in mind. We formulate our products to meet high standards because we knew this day would come.

Whether you are here for the wellness benefits of our CBD or the recreational relaxation of VĪBZ, you are part of a movement that is finally getting the respect it deserves. We are committed to navigating these changes so that you continue to have uninterrupted access to the products you trust.

As regulations tighten and the market matures, stick with brands that value transparency. The "Wild West" days of hemp are ending, and the era of professional, recognized cannabis is beginning. We are ready for it, and we are glad you are with us on this journey.

References

1. Breitbart Politics. (2025, December 18). Trump Signs Order Reclassifying Marijuana as Schedule III Drug. Retrieved from 

2. The White House. (2025, December). Fact Sheet: President Donald J. Trump Is Increasing Medical Marijuana and Cannabidiol Research.